

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-172)

BULEVIRTIDE

PRONUNCIATION

bue le' vir tide

THERAPEUTIC CLAIM

Treatment of chronic hepatitis delta virus infection and compensated liver disease.

CHEMICAL NAMES


1. Glycinamide, *N*-(1-oxotetradecyl)glycyl-L-threonyl-L-asparaginyll-L-leucyl-L-seryl-L-valyl-L-prolyl-L-asparaginyll-L-prolyl-L-leucylglycyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L- $\alpha$ -aspartyl-L-histidyl-L-glutaminyll-L-leucyl-L- $\alpha$ -aspartyl-L-prolyl-L-alanyl-L-phenylalanylglycyl-L-alanyl-L-asparaginyll-L-seryl-L-asparaginyll-L-asparaginyll-L-prolyl-L- $\alpha$ -aspartyl-L-tryptophyll-L- $\alpha$ -aspartyl-L-phenylalanyl-L-asparaginyll-L-prolyl-L-asparaginyll-L-lysyl-L- $\alpha$ -aspartyl-L-histidyl-L-tryptophyll-L-prolyl-L- $\alpha$ -glutamyl-L-alanyl-L-asparaginyll-L-lysyl-L-valyl- (CAS Name)
2. *N*-tetradecanoylglycyl-L-threonyl-L-asparaginyll-L-leucyl-L-seryl-L-valyl-L-prolyl-L-asparaginyll-L-prolyl-L-leucylglycyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L- $\alpha$ -aspartyl-L-histidyl-L-glutaminyll-L-leucyl-L- $\alpha$ -aspartyl-L-prolyl-L-alanyl-L-phenylalanylglycyl-L-alanyl-L-asparaginyll-L-seryl-L-asparaginyll-L-asparaginyll-L-prolyl-L- $\alpha$ -aspartyl-L-tryptophyll-L- $\alpha$ -aspartyl-L-phenylalanyl-L-asparaginyll-L-prolyl-L-asparaginyll-L-lysyl-L- $\alpha$ -aspartyl-L-histidyl-L-tryptophyll-L-prolyl-L- $\alpha$ -glutamyl-L-alanyl-L-asparaginyll-L-lysyl-L-valylglycinamide (IUPAC Name)

STRUCTURAL FORMULA


GTNLSVPNPL GFFPDHQLDP AFGANSNNPD WDFNPNKDHW PEANKVG 47

Modified residues

G  
1  
*N*-myristoylglycine



G  
47  
glycinamide



MOLECULAR FORMULA

C<sub>248</sub>H<sub>355</sub>N<sub>65</sub>O<sub>72</sub>

MOLECULAR WEIGHT

5.40 kDa

TRADEMARKS

Hepcludex™; Myrcludex™

SPONSOR

Gilead Sciences, Inc.

CODE DESIGNATIONS

915207G

CAS REGISTRY NUMBER

2012558-47-1

UNII

WKM56H3TLB

WHO NUMBER

10692

SCS